-+ 0.00%
-+ 0.00%
-+ 0.00%

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

Barchart·07/14/2026 01:30:00
Listen to the news

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers

Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.